Silence Therapeutics to be acquired by Merck KGaA
Silence Therapeutics agreed to an all-cash acquisition by Merck KGaA valuing it at about $1.30 billion, with an enterprise value of $1.10 billion. Shareholders will receive $20 per ADS or $6.67 per ordinary share; securityholders with 14% of voting power signed a support agreement.
1. Acquisition terms
Silence Therapeutics entered into an agreement to be acquired by Merck KGaA in an all-cash deal valuing the company at about $1.30 billion, with an enterprise value of $1.10 billion. Shareholders will receive $20 per ADS or $6.67 per ordinary share, and securityholders with 14% of voting power entered a voting and support agreement.
